Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB - Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, HC Wainwright cut their target price on shares of PDS Biotechnology from $21.00 to $13.00 and set a "buy" rating for the company in a report on Thursday, March 27th.

PDS Biotechnology Stock Performance

PDSB stock traded up $0.03 during trading on Friday, reaching $1.40. The company had a trading volume of 370,153 shares, compared to its average volume of 487,057. The firm has a 50-day simple moving average of $1.23 and a 200-day simple moving average of $1.52. The company has a market cap of $63.99 million, a price-to-earnings ratio of -1.21 and a beta of 1.40. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a twelve month low of $0.85 and a twelve month high of $4.42.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. As a group, sell-side analysts expect that PDS Biotechnology will post -1.2 earnings per share for the current year.

Institutional Investors Weigh In On PDS Biotechnology

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new stake in shares of PDS Biotechnology during the fourth quarter worth $26,000. Blair William & Co. IL grew its holdings in shares of PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock worth $257,000 after buying an additional 35,757 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of PDS Biotechnology during the fourth quarter worth $89,000. Renaissance Technologies LLC grew its holdings in shares of PDS Biotechnology by 331.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock worth $163,000 after buying an additional 76,800 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of PDS Biotechnology by 38.4% during the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock worth $64,000 after buying an additional 10,837 shares in the last quarter. Hedge funds and other institutional investors own 26.84% of the company's stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.